Torretta Sara, Piatti Gioia, Catalano Chiara, Ferrucci Silvia, Cavallini Mirta, Rivolta Federica, Bellocchi Chiara, D'Adda Alice, Battilocchi Ludovica, Tavecchio Simona, Pignataro Lorenzo
Department of Specialist Surgical Sciences, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Italy.
Ther Adv Allergy Rhinol. 2025 Jun 4;16:27534030241312540. doi: 10.1177/27534030241312540. eCollection 2025 Jan-Dec.
Type 2 inflammation plays a pivotal role in various allergic and inflammatory diseases, including chronic rhinosinusitis, asthma, atopic dermatitis, and eosinophilic esophagitis. Dupilumab is one of the emerging therapeutic targets that modulate the key mediators and cellular players involved in type 2 inflammation, aiming to improve the immune response and the quality of life of the patient.
Here, we describe the experience made on 792 patients enrolled by several specialists of a multidisciplinary team working on inflammatory type 2 diseases.
Retrospective study.
Patients were treated with dupilumab according to the prescribed indications and were evaluated by several exams, tests, and questionnaires at baseline (T0) and after 12 (T1), 18 (T2), and 24 (T3) months.
Overall, dupilumab exerts beneficial effects as demonstrated both by patients-reported outcomes and by objective assessments. Compared to baseline, all examined efficacy indicators showed an improvement after 12 months, with positive effects sustained through the 2 years of observation. Our results align with several previous trials.
Understanding the interconnection between different type 2 inflammatory diseases provides insight into potential avenues for precision medicine approaches and targeted therapies.
2型炎症在多种过敏性和炎症性疾病中起关键作用，包括慢性鼻-鼻窦炎、哮喘、特应性皮炎和嗜酸性食管炎。度普利尤单抗是新兴的治疗靶点之一，可调节参与2型炎症的关键介质和细胞成分，旨在改善患者的免疫反应和生活质量。
在此，我们描述了一个多学科团队的几位专家纳入的792例2型炎症性疾病患者的治疗经验。
回顾性研究。
根据规定适应症给患者使用度普利尤单抗，并在基线（T0）以及12（T1）、18（T2）和24（T3）个月后通过多项检查、测试和问卷进行评估。
总体而言，患者报告的结果和客观评估均表明度普利尤单抗具有有益效果。与基线相比，所有检查的疗效指标在12个月后均有改善，且在2年的观察期内效果持续。我们的结果与之前的多项试验一致。
了解不同2型炎症性疾病之间的相互联系有助于深入了解精准医学方法和靶向治疗的潜在途径。
